Form 4: Apellis Pharmaceuticals Grants Stock Options to VP/Chief Accounting Officer James Chopas

Apellis Pharmaceuticals, Inc. has granted 11,250 stock options to James George Chopas, VP/Chief Accounting Officer, with an exercise price of $19.39, vesting over two years.

Summary

• James George Chopas, the VP/Chief Accounting Officer of Apellis Pharmaceuticals, Inc. (APLS), was granted 11,250 stock options.
• The stock options have an exercise price of $19.39 per share.
• The grant date for these options was June 9, 2025.
• The options will vest over a two-year period, with 50% vesting on the one-year anniversary and the remaining 50% vesting on the two-year anniversary of the grant date, contingent upon continued service.
• The expiration date for these stock options is June 9, 2035.
• Following this transaction, Mr. Chopas beneficially owns 11,250 derivative securities directly.

Sentiment

Score: 7

Explanation: The sentiment is moderately positive as it represents a standard executive compensation action that aligns management's interests with shareholders, indicating stability and a commitment to retention. It is not directly impactful on operational or financial performance in the short term but is a positive signal for corporate governance and executive alignment.

Positives

• The grant of stock options aligns the interests of the VP/Chief Accounting Officer with those of the shareholders, incentivizing long-term performance.
• This is a standard form of executive compensation, which can aid in retaining key management personnel.

Future Outlook

The stock options are subject to a two-year vesting schedule, contingent upon continued service, indicating a future commitment from the executive to the company's performance.

Management Comments

• The stock option award was granted on June 9, 2025, and will vest over a two-year period, with 50% vesting on each of the one-year and two-year anniversaries of the grant date, contingent upon continued service.

Industry Context

The granting of stock options to key executives is a common practice in the biotechnology and pharmaceutical industries, serving as a performance incentive and a tool for executive retention. This aligns with typical compensation structures aimed at linking executive rewards to company performance and shareholder value creation.

Comparison to Industry Standards

• The use of stock options with a multi-year vesting schedule is a standard executive compensation practice across the biotech and broader corporate landscape, similar to compensation packages offered by companies like Biogen or Gilead Sciences for their senior executives.
• The specific number of options and exercise price would typically be benchmarked against peer companies of similar market capitalization and stage of development, though no specific comparable companies or projects are detailed in this filing.

Corporate Governance

Related Party Transactions

• The grant of stock options to James George Chopas, an officer of Apellis Pharmaceuticals, Inc., constitutes a related party transaction as it involves compensation provided by the company to a key management personnel.

Stakeholder Impact

• Shareholders: The grant of stock options aims to align the interests of a key executive with shareholders, potentially leading to better long-term performance and value creation.
• Employees: This action reflects the company's compensation strategy for its senior leadership, which can influence overall employee morale and retention strategies.

Next Steps

• The stock options will vest in two tranches: 50% on June 9, 2026, and the remaining 50% on June 9, 2027, assuming continued service.

Key Dates

Recommendation

Keywords

Apellis Pharmaceuticals, APLS, stock options, executive compensation, Form 4, insider transaction, beneficial ownership, James Chopas